Matinas BioPharma Files 8-K
Ticker: MTNB · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Matinas BioPharma filed a standard 8-K, no major news.
AI Summary
Matinas BioPharma Holdings, Inc. filed an 8-K on March 25, 2024, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine update for investors, confirming the company's ongoing compliance and reporting obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no new material information or significant financial disclosures that would indicate immediate risk.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38022 (identifier) — Commission File Number
- 46-3011414 (identifier) — IRS Employer ID Number
- 1545 Route 206 South, Suite 302 (address) — Principal executive offices
- Bedminster, New Jersey (location) — Principal executive offices location
- 07921 (zip_code) — Principal executive offices zip code
- (908) 484-8805 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Matinas BioPharma Holdings, Inc.?
The primary purpose is to report on other events and financial statements as of March 25, 2024, fulfilling regulatory requirements.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 25, 2024.
In which state is Matinas BioPharma Holdings, Inc. incorporated?
Matinas BioPharma Holdings, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive office is located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
Does this filing disclose any new material business developments or financial results?
Based on the provided text, this filing appears to be a routine 8-K reporting on 'Other Events' and 'Financial Statements and Exhibits' without detailing specific new material business developments or financial results.
Filing Stats: 1,339 words · 5 min read · ~4 pages · Grade level 14.6 · Accepted 2024-03-25 08:05:37
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex99-1.htm (EX-99.1) — 27KB
- form8-k_001.jpg (GRAPHIC) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_002.jpg (GRAPHIC) — 56KB
- 0001493152-24-011077.txt ( ) — 416KB
- mtnb-20240325.xsd (EX-101.SCH) — 3KB
- mtnb-20240325_lab.xml (EX-101.LAB) — 33KB
- mtnb-20240325_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated March 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -4-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: March 25, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -5-